AKT1 and cancer: Additionally, activation of the PI3K-Akt pathway by PARP inhibition, a mechanism originally suggested for reducing side effects of platinum compounds and alkylating agents [10], represent a significant limitation of PARP inhibitor utilizing chemotherapy by protecting mitochondrial integrity and function, and mitigating apoptosis in the cancer cells (Figure 2).